INFU vs. AXGN, SIBN, BVS, AVNS, ZIMV, BFLY, KIDS, SMLR, CBLL, and TMCI
Should you be buying InfuSystem stock or one of its competitors? The main competitors of InfuSystem include AxoGen (AXGN), SiBone (SIBN), Bioventus (BVS), Avanos Medical (AVNS), ZimVie (ZIMV), Butterfly Network (BFLY), OrthoPediatrics (KIDS), Semler Scientific (SMLR), CeriBell (CBLL), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry.
InfuSystem vs. Its Competitors
InfuSystem (NYSE:INFU) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.
InfuSystem has higher earnings, but lower revenue than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
InfuSystem has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.
InfuSystem presently has a consensus price target of $13.50, indicating a potential upside of 30.31%. AxoGen has a consensus price target of $25.75, indicating a potential upside of 44.02%. Given AxoGen's higher possible upside, analysts clearly believe AxoGen is more favorable than InfuSystem.
InfuSystem has a net margin of 1.12% compared to AxoGen's net margin of -2.29%. InfuSystem's return on equity of 2.78% beat AxoGen's return on equity.
In the previous week, AxoGen had 20 more articles in the media than InfuSystem. MarketBeat recorded 21 mentions for AxoGen and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 0.81 beat AxoGen's score of 0.70 indicating that InfuSystem is being referred to more favorably in the media.
71.1% of InfuSystem shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 10.2% of InfuSystem shares are held by company insiders. Comparatively, 2.8% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
InfuSystem beats AxoGen on 11 of the 17 factors compared between the two stocks.
Get InfuSystem News Delivered to You Automatically
Sign up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InfuSystem Competitors List
Related Companies and Tools
This page (NYSE:INFU) was last updated on 10/4/2025 by MarketBeat.com Staff
